Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
547.03
-0.86 (-0.16%)
At close: Nov 11, 2026, 4:00 PM EST
542.94
-4.09 (-0.75%)
After-hours: Nov 11, 2026, 7:51 PM EST
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $3.44B in the quarter ending September 30, 2026, with 11.85% growth. This brings the company's total for the last twelve months to $12.95B, up 10.48% year-over-year. In the year 2025, Vertex Pharmaceuticals had annual revenue of $12.00B with 8.90% growth. That makes Vertex Pharmaceuticals the 1,185th largest company in the world by revenue and 386th in the United States.
Revenue (ttm)
$12.95B
Revenue Growth
+10.48%
P/S Ratio
10.71
Revenue / Employee
$2,023,688
Employees
6,400
Market Cap
138.69B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Vertex Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.00B | 981.20M | 8.90% |
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | 4.16B | 1.12B | 36.59% |
| Dec 31, 2018 | 3.05B | 558.95M | 22.46% |
| Dec 31, 2017 | 2.49B | 786.48M | 46.20% |
| Dec 31, 2016 | 1.70B | 669.84M | 64.89% |
| Dec 31, 2015 | 1.03B | 451.92M | 77.86% |
| Dec 31, 2014 | 580.42M | -631.56M | -52.11% |
| Dec 31, 2013 | 1.21B | -315.07M | -20.63% |
| Dec 31, 2012 | 1.53B | 116.42M | 8.25% |
| Dec 31, 2011 | 1.41B | 1.27B | 883.91% |
| Dec 31, 2010 | 143.37M | 41.48M | 40.71% |
| Dec 31, 2009 | 101.89M | -73.62M | -41.94% |
| Dec 31, 2008 | 175.50M | -23.51M | -11.81% |
| Dec 31, 2007 | 199.01M | -17.34M | -8.02% |
| Dec 31, 2006 | 216.36M | 55.47M | 34.47% |
| Dec 31, 2005 | 160.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 16.90B |
| BeOne Medicines AG | 6.45B |
| Incyte | 6.01B |
| argenx SE | 5.92B |
| Genmab | 4.30B |
| BioNTech SE | 2.75B |
| Royalty Pharma | 2.62B |
| Moderna | 2.53B |
VRTX News
- 7 days ago - Vertex to Participate in Upcoming Investor Conferences - Business Wire
- 7 days ago - Vertex Pharmaceuticals Thrives on Higher Sales and Guidance - FXEmpire
- 7 days ago - Vertex Pharmaceuticals price target raised to $626 from $617 at Barclays - TheFly
- 8 days ago - Vertex Pharmaceuticals price target raised to $660 from $558 at Scotiabank - TheFly
- 8 days ago - Vertex Pharmaceuticals price target raised to $620 from $600 at BMO Capital - TheFly
- 8 days ago - Vertex Pharmaceuticals price target raised to $575 from $550 at TD Cowen - TheFly
- 8 days ago - Vertex Pharmaceuticals price target raised to $640 from $615 at UBS - TheFly
- 8 days ago - Vertex Pharmaceuticals price target raised to $600 from $576 at RBC Capital - TheFly